Progress in Target-Therapy with Breast Cancer

Abstract

With the increase of incidence rate of breast cancer, more attention has been paid to the treatment of this disease. This article mainly divides breast cancer into three negative breast cancer and HER2 overexpression breast cancer. Negative breast cancer can be divided into four subtypes, among which immunomodulatory pressure type is more sensitive to immunotherapy. The emergence of immunotherapy has brought new tumor treatment methods for breast cancer, mainly immune-checkpoint inhibitor therapy. The pathological complete response rate was significantly improved in the PD-1 drug development process in combination with neoadjuvant chemotherapy, and the combination therapy of monoclonal antibody and paclitaxel in the PD-L1 drug development process can significantly prolong survival rate. The combination of epeimab and navumab with paclitaxel in the treatment of early triple negative breast cancer is expected to improve ORR and PCR rates. This article briefly describes the development process of targeted therapy for human epidermal growth factor receptor 2, indicating that anti HER2 targeted therapy has entered the era of antibody drug conjugates. At the same time, the different clinical research and development status of PD-1 inhibitor, PD-L1 inhibitor and CTLA-4 inhibitor during immunotherapy also tells us that in the process of treating breast cancer, combined chemotherapy and targeted treatment are more conducive to improving the prognosis and meeting the requirements of patients to improve their quality of life.